A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
Condition: Diabetes Mellitus, Type 2 Interventions: Drug: IcoSema; Drug: Insulin glargine; Drug: insulin aspart Sponsor: Novo Nordisk A/S Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 19, 2021 Category: Research Source Type: clinical trials
